Production of 105Rh-EDTMP and its bone accumulation.
105Rh has favorable physical characteristics as a radiotherapeutic nuclide. Carrier-free 105Rh can be produced by the neutron activation of 104Ru followed by beta decay of 105Ru. It was clarified that carrier-free 105Rh can be produced in quantities and the purity necessary for chemical and clinical investigations of its use as a nuclide for radiotherapy. 105Rh-EDTMP was simply obtained from 105Rh3+ and EDTMP by heating for 30 min in boiling water, giving a radiochemical yield of > 99%. Dissociation of radioactivity assessed by paperchromatography was negligible for up to 5 days after its preparation. In animals, 105Rh-EDTMP showed rapid blood clearance and selective uptake in the bone. Hence, 105Rh-EDTMP is thought to be a promising therapeutic agent for the treatment of pain due to bone metastases.
Ando
A
A
School of Health Sciences, Faculty of Medicine, Kanazawa University, Japan. ando@kenroku.kanazawa-u.ac.jp
Ando
I
I
Tonami
N
N
Kinuya
S
S
Okamoto
N
N
Sugimoto
M
M
Fukuda
N
N
Matsumoto
S
S
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009502:Neutrons; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D063065:Organophosphonates / Q000138:chemical synthesis* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000138:chemical synthesis* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012238:Rhodium / Q000493:pharmacokinetics / Q000627:therapeutic use; D013669:Technetium Tc 99m Medronate / Q000493:pharmacokinetics; D013997:Time Factors; D014018:Tissue Distribution
D009942:Organometallic Compounds; D063065:Organophosphonates; D019275:Radiopharmaceuticals; C405709:rhodium ethylenediaminetetramethylenephosphonate; D012238:Rhodium; D013669:Technetium Tc 99m Medronate